Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,001 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sex Differences in Low-Density Lipoprotein Cholesterol Reduction With PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry.
Cordero A, Fernández Del Olmo MR, Cortez Quiroga GA, Romero-Menor C, Fácila L, Seijas-Amigo J, Fornovi A, Murillo JR, Rodríguez-Mañero M, Bello Mora MC, Valle A, Miriam S, Pamias RF, Bañeras J, García PB, Clemente Lorenzo MM, Sánchez-Alvarez S, López-Rodríguez L, González-Juanatey JR. Cordero A, et al. Among authors: valle a. J Cardiovasc Pharmacol. 2022 Apr 1;79(4):523-529. doi: 10.1097/FJC.0000000000001205. J Cardiovasc Pharmacol. 2022. PMID: 34983910
Prevention of myocardial infarction and stroke with PCSK9 inhibitors treatment: a metanalysis of recent randomized clinical trials.
Cordero A, Rodríguez-Mañero M, Fácila L, Fernández-Olmo MR, Gómez-Martínez MJ, Valle A, Castellano JM, Toro MM, Seijas-Amigo J, Vicedo A, González-Juanatey JR. Cordero A, et al. Among authors: valle a. J Diabetes Metab Disord. 2020 Jun 1;19(2):759-765. doi: 10.1007/s40200-020-00557-6. eCollection 2020 Dec. J Diabetes Metab Disord. 2020. PMID: 33520801 Free PMC article.
Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT).
Rossello X, Raposeiras-Roubin S, Latini R, Dominguez-Rodriguez A, Barrabés JA, Sánchez PL, Anguita M, Fernández-Vázquez F, Pascual-Figal D, De la Torre Hernandez JM, Ferraro S, Vetrano A, Pérez-Rivera JA, Prada-Delgado O, Escalera N, Staszewsky L, Pizarro G, Agüero J, Pocock S, Ottani F, Fuster V, Ibáñez B; REBOOT-CNIC investigators. Rossello X, et al. Eur Heart J Cardiovasc Pharmacother. 2022 May 5;8(3):291-301. doi: 10.1093/ehjcvp/pvab060. Eur Heart J Cardiovasc Pharmacother. 2022. PMID: 34351426 Clinical Trial.
Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry.
Cordero A, Fernández Olmo MR, Cortez Quiroga GA, Romero-Menor C, Fácila L, Seijas-Amigo J, Rondán Murillo J, Sandin M, Rodríguez-Mañero M, Bello Mora MC, Valle A, Fornovi A, Freixa Pamias R, Bañeras J, Blanch García P, Clemente Lorenzo MM, Sánchez-Álvarez S, López-Rodríguez L, González-Juanatey JR. Cordero A, et al. Among authors: valle a. Eur J Clin Invest. 2022 Dec;52(12):e13863. doi: 10.1111/eci.13863. Epub 2022 Sep 5. Eur J Clin Invest. 2022. PMID: 36039486
Cardiorenal benefits of finerenone: protecting kidney and heart.
González-Juanatey JR, Górriz JL, Ortiz A, Valle A, Soler MJ, Facila L. González-Juanatey JR, et al. Among authors: valle a. Ann Med. 2023 Dec;55(1):502-513. doi: 10.1080/07853890.2023.2171110. Ann Med. 2023. PMID: 36719097 Free PMC article. Review.
Vascular protection with rivaroxaban in the comprehensive management of atrial fibrillation.
Escobar-Cervantes C, Díez-Villanueva P, Bonanad Lozano C, Reino AP, Almendro-Delia M, Facila L, Valle A, Suárez C. Escobar-Cervantes C, et al. Among authors: valle a. Expert Rev Cardiovasc Ther. 2023 Jul-Dec;21(11):791-802. doi: 10.1080/14779072.2023.2276893. Epub 2023 Dec 10. Expert Rev Cardiovasc Ther. 2023. PMID: 37933665 Review.
Safety and Efficacy of the Combination of Sacubitril/Valsartan and SGLT2i in HFrEF Patients (SECSI Registry).
Jiménez-Blanco Bravo M, Valle A, Gayán Ordás J, Del Prado Díaz S, Cordero Pereda D, Morillas Climent H, Bascompte Claret R, Seller Moya J, Zamorano Gómez JL, Alonso Salinas GL. Jiménez-Blanco Bravo M, et al. Among authors: valle a. J Cardiovasc Pharmacol. 2021 Nov 1;78(5):e662-e668. doi: 10.1097/FJC.0000000000001111. J Cardiovasc Pharmacol. 2021. PMID: 34321396
Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2 ): a randomized clinical trial.
Palau P, Amiguet M, Domínguez E, Sastre C, Mollar A, Seller J, Garcia Pinilla JM, Larumbe A, Valle A, Gómez Doblas JJ, de la Espriella R, Miñana G, Mezcua AR, Santas E, Bodí V, Sanchis J, Pascual-Figal D, Górriz JL, Baýes-Genís A, Núñez J; DAPA-VO2 Investigators (see Appendix). Palau P, et al. Among authors: valle a. Eur J Heart Fail. 2022 Oct;24(10):1816-1826. doi: 10.1002/ejhf.2560. Epub 2022 Jun 6. Eur J Heart Fail. 2022. PMID: 35604416 Free article. Clinical Trial.
Short-term Changes in Hemoglobin and Changes in Functional Status, Quality of Life and Natriuretic Peptides After Initiation of Dapagliflozin in Heart Failure With Reduced Ejection Fraction.
Lorenzo M, Miñana G, Palau P, Amiguet M, Seller J, Garcia Pinilla JM, Domínguez E, Villar S, DE LA Espriella R, Núñez E, Górriz JL, Valle A, Bodí V, Sanchis J, Bayés-Genis A, Núñez J; DAPA-VO2 Investigators. Lorenzo M, et al. Among authors: valle a. J Card Fail. 2023 May;29(5):849-854. doi: 10.1016/j.cardfail.2023.02.008. Epub 2023 Mar 4. J Card Fail. 2023. PMID: 36871614 Clinical Trial.
1,001 results